Blog
RSS FeedPosted by Michael Wonder on 14 Jan 2016
Regorafenib in metastatic colorectal cancer: still only a hint of a minor additional benefit
4 January 2016 - After the expiry of the decision it made in 2014, the IQWIG has the reached same ...
Posted by Michael Wonder on 13 Jan 2016
ERC recommends Jakavi for patients with polycythema vera who are resistant to or intolerant of hydroxyurea
7 January 2016 - The ERC has recommended the funding of ruxolitinib phosphate (Jakavi) so long as its cost-effectiveness is ...
Posted by Michael Wonder on 13 Jan 2016
Nivolumab in melanoma: data subsequently submitted improve assessment result
7 January 2016 - In an addendum, the IQWiG assessed study data submitted by BMS. In treatment-naive patients whose tumour is ...
Posted by Michael Wonder on 13 Jan 2016
Registration of new chemical entities in Australia in 2015
5 January 2016 - Each year, approximately 40 new prescription medicines containing new active substances are registered. ...
Posted by Michael Wonder on 12 Jan 2016
Pomalidomide in multiple myeloma: no sign of an additional clinical benefit
4 January 2016 - The IQWiG examined whether pomalidomide offers an added benefit over the appropriate comparator therapy. No such added ...
Posted by Michael Wonder on 12 Jan 2016
Dabrafenib in combination with trametinib in advanced melanoma with BRAF V600 mutation: indication of added benefit says IQWiG
4 January 2016 - According to the findings, no added benefit is proven for trametinib monotherapy because of a lack of ...
Posted by Michael Wonder on 12 Jan 2016
Human medicines: EMA highlights of 2015
12 Januaru 2016 - The EMA has released an overview of its 2015 key recommendations in relation to the marketing authorisations ...
Posted by Michael Wonder on 11 Jan 2016
January 2016 SMC decisions news release
11 January 2016 - The Scottish Medicines Consortium, which reviews newly licensed medicines, has today published advice accepting five new medicines ...
Posted by Michael Wonder on 07 Jan 2016
AbbVie's Humira (adalimumab) receives first and only Health Canada approval for moderate to severe hidradenitis suppurativa
6 January 2016 - This follows approval from the FDA and the European Commission. Humira is now the first and only ...
Posted by Michael Wonder on 07 Jan 2016
Additional outcome from the November 2015 PBAC meeting
7 January 2016 - The PBAC decided not to recommend pirfenidone for PBS listing for idiopathic pulmonary fibrosis on the ...
Posted by Michael Wonder on 04 Jan 2016
2015: another strong year for patients in need of new drug therapies
4 January 2016 - In 2015, FDA’s CDER approved 45 novel new therapies – significantly more than the average of 28 ...
Posted by Michael Wonder on 28 Dec 2015
NICE issues revised draft guidance on ezetimibe for hypercholesterolaemia
24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...
Posted by Michael Wonder on 22 Dec 2015
FDA approves Zurampic to treat high blood uric acid levels associated with gout
22 December 2015 - The U.S. FDA today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood ...
Posted by Michael Wonder on 22 Dec 2015
FDA approves new orphan drug to treat pulmonary arterial hypertension
22 December 2015 - On December 21, the U.S. FDA approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension ...
Posted by Michael Wonder on 22 Dec 2015
Evolocumab: no hint of added clinical benefit according the IQWiG in Germany
15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...